NCT00056836View on ClinicalTrials.gov

A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

December 31, 2005

Conditions
Macular Degeneration
Interventions
DRUG

rhuFab V2 (ranibizumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY